Company Overview and News

to your dashboard

Headline News

Large Opportunity For Smaller Arbitrageurs

2017-11-13 seekingalpha
The deal is very small with a total value of roughly $33MM, which will lead to very little institutional attention. (20-2)

BRIEF-Combimatrix Corp stockholders approve merger agreement with Invitae Corp

2017-11-10 reuters
* Combimatrix Corp says ‍approximately 1.79 million of common shares voting in meeting voted in favor of approval & adoption of all-stock merger agreement​ Source text for Eikon: Further company coverage: (20-0)

Week 324: Underlying Conditions

2017-09-27 seekingalpha
See the end of the post for my full portfolio breakdown and the last four weeks of trades. (81-5)

BRIEF-CombiMatrix Corp says co's unit entered into Marketing and Laboratory Services Agreement with Invitae Corp and its unit

2017-09-27 reuters
* CombiMatrix Corp - ‍on Sept 25, co’s unit CombiMatrix Molecular Diagnostics Inc entered into marketing and laboratory services agreement with Invitae Corp and its unit (20-0)

CombiMatrix Sets Record Date And Special Stockholders Meeting Date Regarding Proposed Merger With Invitae

2017-09-25 devicespace
IRVINE, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX) (“CombiMatrix” or the “Company”), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announced today it has set important dates for a special meeting of its stockholders to vote on matters related to the proposed merger with Invitae Corporation (“Invitae”). (35-0)

BRIEF-CombiMatrix sets record date and special stockholders meeting date regarding proposed merger

2017-09-25 reuters
* CombiMatrix Corp - Merger has been unanimously approved by boards of directors of both companies (2-0)

MMCAP International Inc. SPC discloses 5.53% ownership in CBMX / CombiMatrix Corp. -

August 22, 2017 - MMCAP International Inc. SPC has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 161,469 shares of CombiMatrix Corp. (NASDAQ:CBMX). This represents 5.5322 percent ownership of the company.

Stonepine Capital Management, LLC opens position in CBMX / CombiMatrix Corp. -

August 09, 2017 - Stonepine Capital Management, LLC has filed a SC 13G form disclosing ownership of 290,000 shares of CombiMatrix Corp. (NASDAQ:CBMX) corresponding to a(n) 9.96 ownership percentage. (0-1)

Invitae's Growth Plans Get Bolder

2017-08-02 seekingalpha
It was a big day Tuesday for genetic testing concern Invitae which rose some 8% on the day in a down market for biotech

Invitae To Acquire Good Start Genetics And CombiMatrix

2017-08-01 seekingalpha
Good Start Genetics provides pre-pregnancy screening; CombiMatrix also provides pre-pregnancy screening as well as post-pregnancy diagnostics.

Invitae Acquiring Good Start Genetics And CombiMatrix, Adding Comprehensive Reproductive Health Capabilities To Serve Every Stage Of Life

2017-08-01 devicespace
SAN FRANCISCO, July 31, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced two acquisitions to establish a leading position in family health genetic information services. Invitae has entered into a definitive agreement to acquire privately held Good Start Genetics, a molecular diagnostics company focused on preimplantation and carrier screening for inherited disorders.

Invitae Acquiring Good Start Genetics and CombiMatrix, Adding Comprehensive Reproductive Health Capabilities to Serve Every Stage of Life

2017-07-31 prnewswire
-- Good Start Genetics Provides Best-in-Class Carrier and NGS Preimplantation Screening to Leading IVF Centers -- -- CombiMatrix Trusted for Advanced DNA Diagnostics by Reproductive Health and Pediatric Specialists -- -- Invitae to Host Webcast for Investors on August 1 at 8 am ET / 5 am PT --

Preimplantation Genetic Testing Market Worth 541.8 Million USD by 2022

2017-07-13 prnewswire
According to a new market research report "Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022", published by MarketsandMarkets™, the Global Preimplantation Genetic Testing Market is projected to reach USD 541.

Portfolio Update Heading Into Q2

2017-07-09 seekingalpha
The weather is too nice to be spending cycles on the blog, so here's a quick summary of where I stand. Top 20% performers in green.

CUSIP: 20009T501